The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Diabetic Retinopathy Market Research Report 2024

Global Diabetic Retinopathy Market Research Report 2024

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1713586

No of Pages : 89

Ask Your Query

Synopsis

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.

Global Diabetic Retinopathy market is projected to reach US$ 11920 million in 2029, increasing from US$ 7758.6 million in 2022, with the CAGR of 6.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Diabetic Retinopathy market research.

Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Diabetic Retinopathy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  •     Bayer
  •     Roche
  •     Novartis
  •     TEVA
  •     Alimera Sciences
  •     Regeneron Pharmaceuticals
  •     Boehringer Ingelheim
  •     Kowa Group
  •     Ohr Pharmaceutical
  •     Quark Pharmaceuticals

Segment by Type

  •     Laser Surgery
  •     Injection of Corticosteroids
  •     Anti-VEGF Drugs
  •     Vitrectomy

Segment by Application

  •     Hospitals
  •     Clinics
  •     Others

By Region

  •  North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Diabetic Retinopathy report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

 

Index

 

  1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Diabetic Retinopathy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Laser Surgery
        1.2.3 Injection of Corticosteroids
        1.2.4 Anti-VEGF Drugs
        1.2.5 Vitrectomy
    1.3 Market by Application
        1.3.1 Global Diabetic Retinopathy Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Diabetic Retinopathy Market Perspective (2018-2029)
    2.2 Diabetic Retinopathy Growth Trends by Region
        2.2.1 Global Diabetic Retinopathy Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Diabetic Retinopathy Historic Market Size by Region (2018-2023)
        2.2.3 Diabetic Retinopathy Forecasted Market Size by Region (2024-2029)
    2.3 Diabetic Retinopathy Market Dynamics
        2.3.1 Diabetic Retinopathy Industry Trends
        2.3.2 Diabetic Retinopathy Market Drivers
        2.3.3 Diabetic Retinopathy Market Challenges
        2.3.4 Diabetic Retinopathy Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Diabetic Retinopathy Players by Revenue
        3.1.1 Global Top Diabetic Retinopathy Players by Revenue (2018-2023)
        3.1.2 Global Diabetic Retinopathy Revenue Market Share by Players (2018-2023)
    3.2 Global Diabetic Retinopathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Diabetic Retinopathy Revenue
    3.4 Global Diabetic Retinopathy Market Concentration Ratio
        3.4.1 Global Diabetic Retinopathy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy Revenue in 2022
    3.5 Diabetic Retinopathy Key Players Head office and Area Served
    3.6 Key Players Diabetic Retinopathy Product Solution and Service
    3.7 Date of Enter into Diabetic Retinopathy Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Diabetic Retinopathy Breakdown Data by Type
    4.1 Global Diabetic Retinopathy Historic Market Size by Type (2018-2023)
    4.2 Global Diabetic Retinopathy Forecasted Market Size by Type (2024-2029)

 5 Diabetic Retinopathy Breakdown Data by Application
    5.1 Global Diabetic Retinopathy Historic Market Size by Application (2018-2023)
    5.2 Global Diabetic Retinopathy Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Diabetic Retinopathy Market Size (2018-2029)
    6.2 North America Diabetic Retinopathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Diabetic Retinopathy Market Size by Country (2018-2023)
    6.4 North America Diabetic Retinopathy Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Diabetic Retinopathy Market Size (2018-2029)
    7.2 Europe Diabetic Retinopathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Diabetic Retinopathy Market Size by Country (2018-2023)
    7.4 Europe Diabetic Retinopathy Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Diabetic Retinopathy Market Size (2018-2029)
    8.2 Asia-Pacific Diabetic Retinopathy Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Diabetic Retinopathy Market Size by Region (2018-2023)
    8.4 Asia-Pacific Diabetic Retinopathy Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Diabetic Retinopathy Market Size (2018-2029)
    9.2 Latin America Diabetic Retinopathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Diabetic Retinopathy Market Size by Country (2018-2023)
    9.4 Latin America Diabetic Retinopathy Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Diabetic Retinopathy Market Size (2018-2029)
    10.2 Middle East & Africa Diabetic Retinopathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Diabetic Retinopathy Market Size by Country (2018-2023)
    10.4 Middle East & Africa Diabetic Retinopathy Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Bayer
        11.1.1 Bayer Company Detail
        11.1.2 Bayer Business Overview
        11.1.3 Bayer Diabetic Retinopathy Introduction
        11.1.4 Bayer Revenue in Diabetic Retinopathy Business (2018-2023)
        11.1.5 Bayer Recent Development
    11.2 Roche
        11.2.1 Roche Company Detail
        11.2.2 Roche Business Overview
        11.2.3 Roche Diabetic Retinopathy Introduction
        11.2.4 Roche Revenue in Diabetic Retinopathy Business (2018-2023)
        11.2.5 Roche Recent Development
    11.3 Novartis
        11.3.1 Novartis Company Detail
        11.3.2 Novartis Business Overview
        11.3.3 Novartis Diabetic Retinopathy Introduction
        11.3.4 Novartis Revenue in Diabetic Retinopathy Business (2018-2023)
        11.3.5 Novartis Recent Development
    11.4 TEVA
        11.4.1 TEVA Company Detail
        11.4.2 TEVA Business Overview
        11.4.3 TEVA Diabetic Retinopathy Introduction
        11.4.4 TEVA Revenue in Diabetic Retinopathy Business (2018-2023)
        11.4.5 TEVA Recent Development
    11.5 Alimera Sciences
        11.5.1 Alimera Sciences Company Detail
        11.5.2 Alimera Sciences Business Overview
        11.5.3 Alimera Sciences Diabetic Retinopathy Introduction
        11.5.4 Alimera Sciences Revenue in Diabetic Retinopathy Business (2018-2023)
        11.5.5 Alimera Sciences Recent Development
    11.6 Regeneron Pharmaceuticals
        11.6.1 Regeneron Pharmaceuticals Company Detail
        11.6.2 Regeneron Pharmaceuticals Business Overview
        11.6.3 Regeneron Pharmaceuticals Diabetic Retinopathy Introduction
        11.6.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Business (2018-2023)
        11.6.5 Regeneron Pharmaceuticals Recent Development
    11.7 Boehringer Ingelheim
        11.7.1 Boehringer Ingelheim Company Detail
        11.7.2 Boehringer Ingelheim Business Overview
        11.7.3 Boehringer Ingelheim Diabetic Retinopathy Introduction
        11.7.4 Boehringer Ingelheim Revenue in Diabetic Retinopathy Business (2018-2023)
        11.7.5 Boehringer Ingelheim Recent Development
    11.8 Kowa Group
        11.8.1 Kowa Group Company Detail
        11.8.2 Kowa Group Business Overview
        11.8.3 Kowa Group Diabetic Retinopathy Introduction
        11.8.4 Kowa Group Revenue in Diabetic Retinopathy Business (2018-2023)
        11.8.5 Kowa Group Recent Development
    11.9 Ohr Pharmaceutical
        11.9.1 Ohr Pharmaceutical Company Detail
        11.9.2 Ohr Pharmaceutical Business Overview
        11.9.3 Ohr Pharmaceutical Diabetic Retinopathy Introduction
        11.9.4 Ohr Pharmaceutical Revenue in Diabetic Retinopathy Business (2018-2023)
        11.9.5 Ohr Pharmaceutical Recent Development
    11.10 Quark Pharmaceuticals
        11.10.1 Quark Pharmaceuticals Company Detail
        11.10.2 Quark Pharmaceuticals Business Overview
        11.10.3 Quark Pharmaceuticals Diabetic Retinopathy Introduction
        11.10.4 Quark Pharmaceuticals Revenue in Diabetic Retinopathy Business (2018-2023)
        11.10.5 Quark Pharmaceuticals Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock